Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Change in Acquisitions & Divestments: 2013-2025

Historic Change in Acquisitions & Divestments for Capricor Therapeutics (CAPR) over the last 9 years, with Sep 2025 value amounting to $78.2 million.

  • Capricor Therapeutics' Change in Acquisitions & Divestments rose 257.66% to $78.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $214.1 million, marking a year-over-year increase of 121.36%. This contributed to the annual value of $93.8 million for FY2024, which is 10.33% down from last year.
  • As of Q3 2025, Capricor Therapeutics' Change in Acquisitions & Divestments stood at $78.2 million, which was up 2.87% from $76.0 million recorded in Q2 2025.
  • Over the past 5 years, Capricor Therapeutics' Change in Acquisitions & Divestments peaked at $78.2 million during Q3 2025, and registered a low of $14.0 million during Q2 2022.
  • For the 3-year period, Capricor Therapeutics' Change in Acquisitions & Divestments averaged around $36.0 million, with its median value being $28.2 million (2023).
  • In the last 5 years, Capricor Therapeutics' Change in Acquisitions & Divestments crashed by 48.86% in 2023 and then skyrocketed by 257.66% in 2025.
  • Over the past 4 years, Capricor Therapeutics' Change in Acquisitions & Divestments (Quarterly) stood at $38.4 million in 2022, then plummeted by 48.86% to $19.6 million in 2023, then fell by 14.89% to $16.7 million in 2024, then soared by 257.66% to $78.2 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $78.2 million for Q3 2025, versus $76.0 million for Q2 2025 and $43.2 million for Q1 2025.